钙化影响HER2阳性乳腺癌新辅助化疗后病理完全缓解及MRI预测
该回顾性研究纳入732例接受多西他赛、卡铂、曲妥珠单抗和帕妥珠单抗新辅助化疗后手术的HER2阳性乳腺癌患者,评估与pCR相关的因素及钙化是否影响MRI放射学完全缓解(rCR)预测pCR的性能。无钙化与较高的pCR率相关,且无钙化患者中rCR预测pCR的阳性预测值更高;当pCR定义从ypT0扩展至ypT0/Tis时,有无钙化患者间pCR率无显著差异。
要点
- 无钙化与更高的pCR率相关(OR 1.65,95%CI 1.15-2.37,P=.006)。
- 有钙化患者中rCR预测pCR的PPV低于无钙化患者(60.0% vs 73.1%,P=.01)。
- MRI显示rCR预测pCR的OR为7.33(95%CI 5.18-10.38,P<.001)。
核心结论
- 在HER2阳性乳腺癌患者中,无钙化与更高的pCR率及更高的MRI rCR预测pCR的PPV相关。
研究设计与样本
- 回顾性研究纳入732例HER2阳性乳腺癌患者(平均年龄51.9岁±10.3),均接受新辅助多西他赛、卡铂、曲妥珠单抗和帕妥珠单抗治疗并于2021年1月至2023年10月间手术,采用逻辑回归分析临床病理因素及乳腺X线和MRI影像特征与pCR的关联,采用χ2检验比较有无钙化患者间MRI rCR预测pCR的诊断性能。
诊断标准与关键数值
- 与pCR相关的因素包括雌激素受体低表达亚型(OR 3.07,95%CI 1.31-7.21,P=.006)、激素受体阴性亚型(OR 3.28,95%CI 2.16-4.98,P<.001)、无钙化(OR 1.65,95%CI 1.15-2.37,P=.006)及MRI rCR(OR 7.33,95%CI 5.18-10.38,P<.001);有钙化 vs 无钙化患者pCR率37.1% vs 48.4%(P=.003),rCR预测pCR的PPV 60.0% vs 73.1%(P=.01);当pCR定义从ypT0扩展至ypT0/Tis时,有钙化 vs 无钙化患者pCR率62.0% vs 58.5%(P=.35)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023. The association of clinicopathologic factors and imaging features at mammography and MRI with pCR was analyzed using logistic regression. The diagnostic performance of rCR at MRI for predicting pCR was compared between patients with and without calcifications using the χ2 test. Results Among the 732 patients included (mean age, 51.9 years ± 10.3 [SD]), 64.8% (474 of 732) had calcifications, 47.0% (344 of 732) had rCR at MRI, and 41.1% (301 of 732) had pCR. The factors associated with pCR included the estrogen receptor-low subtype (odds ratio [OR], 3.07 [95% CI: 1.31, 7.21]; P = .006), the hormone receptor-negative subtype (OR, 3.28 [95% CI: 2.16, 4.98]; P < .001), absence of calcifications (OR, 1.65 [95% CI: 1.15, 2.37]; P = .006), and rCR at MRI (OR, 7.33 [95% CI: 5.18, 10.38]; P < .001). The pCR rate and positive predictive value (PPV) of rCR at MRI were lower in patients with calcifications than in patients without calcifications (pCR, 37.1% vs 48.4%, P = .003; PPV, 60.0% vs 73.1%, P = .01). When the pCR definition was broadened from ypT0 to ypT0/Tis, there was no evidence of a difference in pCR rate between patients with and without calcifications (62.0% vs 58.5%; P = .35). Conclusion In patients with HER2-positive breast cancer, the absence of calcifications was associated with a higher pCR rate and a higher PPV for rCR at MRI for predicting pCR. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Grimm in this issue.
引用
- Ko ES, Yu JH, Woo SY, et al. Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer. Radiology. 2025. PMID: 40923884. doi:10.1148/radiol.250718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。